Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation.

Journal Article (Clinical Trial;Journal Article)

Campath-1H (alemtuzumab) induction was used for renal transplantation in combination with sirolimus as immunosuppression. We previously reported a high (28%) rate of early rejection with this regimen, and now report 3-year outcomes. Twenty-nine patients were recipients of either deceased donor or non-HLA (Human Leukocyte Antigen) identical living donor primary renal allografts. Clinical parameters including infection, malignancy, kidney function, and kidney histology were followed prospectively for 3 years. Three-year cumulative graft and patient survival were 96% and 100%, respectively. Twenty patients were maintained on steroid-free immunosuppressive regimens, and 15 patients were maintained on monotherapy for immunosuppression (12 on sirolimus). No serious infectious complications were observed and two patients developed basal cell skin cancer. The 3-year results of our initial pilot study demonstrate good graft (96%) and patient (100%) outcomes. Campath-1H induction has yielded a high proportion of patients maintained on immunosuppressive monotherapy (57%) without serious infectious- and no malignancy-related complications. The reported regimen yielded novel insights into both Campath-1H and sirolimus therapy in renal transplantation. Because of the higher incidence of early rejection, we recommend a modified strategy of immunosuppression including a brief course of a calcineurin inhibitor.

Full Text

Duke Authors

Cited Authors

  • Barth, RN; Janus, CA; Lillesand, CA; Radke, NA; Pirsch, JD; Becker, BN; Fernandez, LA; Thomas Chin, L; Becker, YT; Odorico, JS; D'Alessandro, AM; Sollinger, HW; Knechtle, SJ

Published Date

  • November 2006

Published In

Volume / Issue

  • 19 / 11

Start / End Page

  • 885 - 892

PubMed ID

  • 17018123

International Standard Serial Number (ISSN)

  • 0934-0874

Digital Object Identifier (DOI)

  • 10.1111/j.1432-2277.2006.00388.x


  • eng

Conference Location

  • Switzerland